Literature DB >> 89133

Occult progressive renal damage in the elderly male due to benign prostatic hypertrophy.

E Mukamel, I Nissenkorn, G Boner, C Servadio.   

Abstract

A review of the case histories of 345 patients who underwent protatectomy showed that 1.7 percent (6 patients) had "occult and progessive renal damage" secondary to prostatic hypertrophy. All these men were over the age of 60 and the disturbances in micturition were so mild that the patients were unaware of, or chose to ignore them. The presenting symptoms were nonspecific and included generalized weakness, anorexia, nausea, constipation, and weight loss. Investigation revealed impaired renal function of varying degrees. Prostatectomy was associated with a dramatic improvement in all 6 patients. Physicians should be aware of the clinical entity of occult and progressive renal damage secondary to obstruction of the bladder outlet, especially in the elderly male. Uremia can develop with minimal urinary symptoms. Elderly men often suppress or deny their symptoms because of the fear of operation.

Entities:  

Mesh:

Year:  1979        PMID: 89133     DOI: 10.1111/j.1532-5415.1979.tb01676.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  4 in total

Review 1.  Benign prostatic hyperplasia and its treatment.

Authors:  J B Stimson; S D Fihn
Journal:  J Gen Intern Med       Date:  1990 Mar-Apr       Impact factor: 5.128

2.  Benign prostatic hyperplasia.

Authors:  R Cygan; L Rucker
Journal:  West J Med       Date:  1984-10

3.  Office evaluation of male patients with lower urinary tract symptoms.

Authors:  Shahin Tabatabaei; Saman Shafaat Talab; Mahdi Zangi; Henry H Woo
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

Review 4.  An overview of benign prostatic hyperplasia and its appreciation in Greco-Arab (Unani) system of medicine.

Authors:  Shabir Ahmad Bhat; Shameem Ahmad Rather; Naquibul Islam
Journal:  Asian J Urol       Date:  2021-05-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.